General Hematology
Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations.
2 Jul, 2021 | 11:39h | UTCCommentary: Blood clots related to AstraZeneca/Oxford vaccine can be mitigated with early detection – MedicalXpress
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome.
30 Jun, 2021 | 10:13h | UTC
Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.
29 Jun, 2021 | 10:07h | UTCThrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine
EBM Analysis | Does tranexamic acid work for everything? For anything?
29 Jun, 2021 | 09:53h | UTCDoes TXA work for everything? For anything? – First10EM
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach.
23 Jun, 2021 | 10:23h | UTC
Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.
21 Jun, 2021 | 08:48h | UTC
Review: venous and arterial thromboembolism in patients with cancer.
16 Jun, 2021 | 08:20h | UTCSummary: Venous and Arterial Thromboembolism in Patients With Cancer – American College of Cardiology
RCT: In patients with atrial fibrillation or mechanical heart valves treated with warfarin undergoing surgery, postoperative bridging treatment with low molecular weight heparin did not prevent major thromboembolism.
11 Jun, 2021 | 08:19h | UTC
Commentary on Twitter
P-E-R-S-E-V-E-R-A-N-C-E = 15 yrs from start to BMJ publication. Bottom line: in pts with atrial fibrillation or mechanical heart valves who had warfarin interrupted for a procedure, we found no benefit of
postop LMWH bridging to prevent major
thromboembolism @canvector @CIHR_ICRH https://t.co/9z0XTQgsbA— Susan R Kahn (@SusanRKahn1) June 10, 2021
M-A: Safety of thoracentesis and tube thoracostomy in patients with uncorrected coagulopathy.
11 Jun, 2021 | 08:15h | UTCCommentary: Is Thoracentesis Safe in Coagulopathic Patients? – JournalFeed
Case series: Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia.
10 Jun, 2021 | 09:46h | UTC
RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.
7 Jun, 2021 | 00:01h | UTC
Commentary on Twitter
Thanks @CMichaelGibson. Another important contribution from the Brazilian Coalition team and investigators in Brazil. Our 6th trial completed in 12 months. Go coalition!!!! https://t.co/TDUr1RukuW
— Renato D Lopes (@RenatoDLopes1) June 4, 2021
Review: Management of patients with venous thromboembolism after the initial treatment period.
8 Jun, 2021 | 09:13h | UTC
Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
6 Jun, 2021 | 23:55h | UTC
Update on the diagnosis and treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome.
6 Jun, 2021 | 23:37h | UTCUpdate on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review – JAMA Oncology (free for a limited period)
Transfusion management of severe anemia in African children: a consensus algorithm.
25 May, 2021 | 08:32h | UTC
[Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups.
18 May, 2021 | 08:04h | UTCTherapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 – medRxiv
Commentary on Twitter
Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support. https://t.co/TkhGs5qow5
— Ryan Zarychanski (@RZarychanski) May 17, 2021
#ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.
18 May, 2021 | 08:01h | UTCAntiCoagulaTIon cOroNavirus – ACTION – American College of Cardiology
Commentary: ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 – TCTMD
#ACC21 – RCT: Clopidogrel better than aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.
18 May, 2021 | 07:34h | UTCAspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial – The Lancet (free registration required)
Commentaries: Harmonizing Optimal Strategy for Treatment of coronary artery diseases-EXtended Antiplatelet Monotherapy – HOST-EXAM – American College of Cardiology AND Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM – TCTMD
Commentary on Twitter
The sensational news of the day comes from South Korea. In a timely comparison of single antiplatelet monotherapies, clopidogrel beats aspirin during the chronic maintenance period after PCI, with curves diverging at 9 months. #ACC21https://t.co/Pp49LxcNWf pic.twitter.com/J9Un4QHzgL
— Davide Capodanno (@DFCapodanno) May 16, 2021
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
17 May, 2021 | 08:56h | UTCInvited commentary: Convalescent plasma in patients hospitalised with COVID-19
Commentaries on Twitter
Convalescent plasma:
Yet another example of
Don’t guess, don’t gamble
Randomize… and learn
I’ve heard it said that it was deemed “too difficult” to do a randomised controlled trial. Really? If that’s the case, we must (and can) fix that problem. Pts deserve better. https://t.co/zxIiK5U63v
— Martin Landray (@MartinLandray) May 15, 2021
NEW #COVID19 research—In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Read https://t.co/7Sbe8V9THp. #RECOVERY #RECOVERYtrial pic.twitter.com/D0OLZKxZc4
— The Lancet (@TheLancet) May 16, 2021
#ACC21 – RCT: No significant differences in cardiovascular events or major bleeding between patients receiving 81 mg vs. 325 mg of aspirin daily.
17 May, 2021 | 08:31h | UTCComparative Effectiveness of Aspirin Dosing in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE – TCTMD AND Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness – ADAPTABLE – American College of Cardiology
Video: Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial
2 recent meta-analysis highlight the benefits of short term (30 days) dual antiplatelet therapy with aspirin + clopidogrel in patients within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke.
17 May, 2021 | 08:16h | UTCMeta-analysis 1: Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials – Stroke
Meta-analysis 2: Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials – Circulation (link to abstract – $ for full-text)
Commentary: Dual vs. Monotherapy Antiplatelet Agents in Secondary Stroke Prevention – American College of Cardiology
Related Guideline: Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke – The BMJ
[Preprint] Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine – Overall risk is 1 in 139,000; for age 65 and over, about 1 in 1,000,000; for age under 55, between 1 in 20,000 to 60,000.
12 May, 2021 | 08:45h | UTC
Systematic review: Use of compression stockings by airline passengers can reduce symptomless deep vein thrombosis and leg edema
11 May, 2021 | 09:04h | UTCCompression stockings for preventing deep vein thrombosis in airline passengers – Cochrane Library
Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.
7 May, 2021 | 08:33h | UTCEditorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ
Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre
Commentary on Twitter
NEW research sheds more light on rate of rare blood clots after Oxford-AstraZeneca vaccine
Rate of adverse events low; benefits of the vaccine still outweigh risks in most situations, say researchershttps://t.co/LslgvzWlWi @Pottegard
— The BMJ (@bmj_latest) May 6, 2021
What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest
5 May, 2021 | 08:37h | UTC